3E Bioventures

3E Bioventures is a venture capital firm specializing in growth capital.

Business Model:

Revenue: $0

Employees: 0-0

Rankings

Industries / Tags:

Detailed 3E Bioventures Information

Geographic Data

3E Bioventures headquarters map

Address: One First Street Suite 18

City: Los Altos

State: CA

Zip: 94022

Country: US

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

3,879,630Website Global Rank

3,030Website Monthly Traffic

Twitter Followers

Description

3E Bioventures Capital is a healthcare focused venture investment fund. The core 3E investment team members are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The 3E team combines good global industry perspectives with practical on the ground China experiences, the team’s past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. 3E Bioventures Capital currently manages both RMB and US Dollar funds, investing in early and growing stage companies in China and overseas. They believe in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years. They aim to leverage their healthcare expertise and experience to ride this historic opportunity, to help build successful healthcare ventures and technologies, to generate good return for their investors, and at the same time, to build 3E Bioventures into a significant international healthcare investment brand.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
2/2021 Cullgen Series B 0
12/2021 Zhengli Technology Venture Round -
1/2016 Refuge Biotechnologies Series A 8.9M
9/2022 Si Peng Technology Angel Round -
12/2015 Profusa Series B 13.2M
9/2018 Cytek Biosciences Series C -
11/2021 Novlead Biotech Series B 18.8M
1/2017 OncoImmune Series A 15M
10/2019 Ansun BioPharma Series B 100M
2/2022 Dewpoint Therapeutics Series C 0
8/2018 Apexigen Series C 58M
3/2020 Apexigen Series C 65M
9/2020 OncoImmune Series B 56M
5/2021 Alebund Pharmaceuticals Series B 0
3/2020 Lipidio Pharmaceuticals Series A -
12/2021 ITabMed Series A 20M
11/2022 Subtle Medical Series B 25M
4/2017 EpimAb Biotherapeutics Series A 25M
5/2018 Refuge Biotechnologies Series B 0
1/2021 Cardea Bio Series A 0
8/2018 Profusa Series C 0
9/2020 Biocytogen Series D 143M
8/2021 NeuralGalaxy Series A 0
4/2018 Biocytogen Series C 65.3M
12/2018 Medtrum Series C 29.1M
5/2018 Ansun BioPharma Series A 85M
8/2022 Regenacy Pharmaceuticals Series B 0
3/2020 Regenacy Pharmaceuticals Series A -
9/2016 MicuRx Pharmaceuticals Series C 55M
4/2023 Xunyuan Technology Angel Round -
1/2023 Junhemeng Biopharmaceutical Series A 0
1/2022 Dermaliq Therapeutics Series A 0
11/2017 Ligatech Bioscience Series A -
5/2023 Larkspur Biosciences Series A 0
2/2023 Eluminex Biosciences Series B 40M
9/2021 Alebund Pharmaceuticals Series B 0
6/2023 Novlead Biotech Series B -
11/2020 Subtle Medical Series A 12.2M
8/2019 Biocytogen Series D 77.1M
3/2022 CytoNiche Series B 0
12/2021 Boaoxin Venture Round 0
3/2018 Eucure Biopharma Series B 19.1M
6/2020 C4 Therapeutics Series B 150M
8/2019 Doctor Shaoyang Series A 7.1M
5/2023 Larkspur Biosciences Series A 0
4/2023 Xunyuan Technology Angel Round -
2/2023 Eluminex Biosciences Series B 0
1/2023 Junhemeng Biopharmaceutical Series A 0
9/2022 Si Peng Technology Angel Round -
8/2022 Regenacy Pharmaceuticals Series B 0
3/2022 CytoNiche Series B 0
2/2022 Dewpoint Therapeutics Series C 0
1/2022 Dermaliq Therapeutics Series A 0
12/2021 Zhengli Technology Venture Round -

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research